Literature DB >> 18316372

E1a gene expression blocks the ERK1/2 signaling pathway by promoting nuclear localization and MKP up-regulation: implication in v-H-Ras-induced senescence.

Juan L Callejas-Valera1, Juan Guinea-Viniegra, Carmen Ramírez-Castillejo, Juan A Recio, Eva Galan-Moya, Natalia Martinez, Jose M Rojas, Santiago Ramón y Cajal, Ricardo Sánchez-Prieto.   

Abstract

In response to oncogenic signals, cells have developed safe mechanisms to avoid transformation through activation of a senescence program. Upon v-H-Ras overexpression, normal cells undergo senescence through several cellular processes, including activation of the ERK1/2 pathway. Interestingly, the E1a gene from adenovirus 5 has been shown to rescue cells from senescence by a yet unknown mechanism. We investigated whether E1a was able to interfere with the ERK1/2 signaling pathway to rescue cells from v-H-Ras-mediated senescence. Our results show that, E1a overexpression blocks v-H-Ras-mediated ERK1/2 activation by two different and concomitant mechanisms. E1a through its ability to interfere with PKB/Akt activation induces the down-regulation of the PEA15 protein, an ERK1/2 nuclear export factor, leading to nuclear accumulation of ERK1/2. In addition to this, we show that E1a increases the expression of the inducible ERK1/2 nuclear phosphatases (MAPK phosphatases) MKP1/DUSP1 and DUSP5, which leads to ERK1/2 dephosphorylation. We confirmed our observations in the human normal diploid fibroblasts IMR90, in which we could also show that an E1a mutant, unable to bind retinoblastoma protein (pRb), cannot rescue cells from v-H-Ras-induced senescence. In conclusion, E1a is able to rescue from Ras-induced senescence by affecting ERK1/2 localization and phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18316372     DOI: 10.1074/jbc.M709230200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Tumor suppressor activity of the ERK/MAPK pathway by promoting selective protein degradation.

Authors:  Xavier Deschênes-Simard; Marie-France Gaumont-Leclerc; Véronique Bourdeau; Frédéric Lessard; Olga Moiseeva; Valérie Forest; Sebastian Igelmann; Frédérick A Mallette; Marc K Saba-El-Leil; Sylvain Meloche; Fred Saad; Anne-Marie Mes-Masson; Gerardo Ferbeyre
Journal:  Genes Dev       Date:  2013-04-18       Impact factor: 11.361

2.  E1a promotes c-Myc-dependent replicative stress: implications in glioblastoma radiosensitization.

Authors:  María Llanos Valero; Francisco Jose Cimas; Laura Arias; Pedro Melgar-Rojas; Elena García; Juan Luis Callejas-Valera; Jesús García-Cano; Leticia Serrano-Oviedo; Miguel Ángel de la Cruz-Morcillo; Isabel Sánchez-Pérez; Ricardo Sánchez-Prieto
Journal:  Cell Cycle       Date:  2013-10-11       Impact factor: 4.534

3.  Mutation of the Rb1 pathway leads to overexpression of mTor, constitutive phosphorylation of Akt on serine 473, resistance to anoikis, and a block in c-Raf activation.

Authors:  Shahenda El-Naggar; Yongqing Liu; Douglas C Dean
Journal:  Mol Cell Biol       Date:  2009-08-24       Impact factor: 4.272

4.  AKT alters genome-wide estrogen receptor alpha binding and impacts estrogen signaling in breast cancer.

Authors:  Poornima Bhat-Nakshatri; Guohua Wang; Hitesh Appaiah; Nikhil Luktuke; Jason S Carroll; Tim R Geistlinger; Myles Brown; Sunil Badve; Yunlong Liu; Harikrishna Nakshatri
Journal:  Mol Cell Biol       Date:  2008-10-06       Impact factor: 4.272

5.  Multiple domains in the 50 kDa form of E4F1 regulate promoter-specific repression and E1A trans-activation.

Authors:  Robert J Rooney
Journal:  Gene       Date:  2020-06-11       Impact factor: 3.688

6.  A cellular threshold for active ERK1/2 levels determines Raf/MEK/ERK-mediated growth arrest versus death responses.

Authors:  Seung-Keun Hong; Pui-Kei Wu; Jong-In Park
Journal:  Cell Signal       Date:  2017-10-03       Impact factor: 4.315

7.  GnRH receptor activation competes at a low level with growth signaling in stably transfected human breast cell lines.

Authors:  Kevin Morgan; Colette Meyer; Nicola Miller; Andrew H Sims; Ilgin Cagnan; Dana Faratian; David J Harrison; Robert P Millar; Simon P Langdon
Journal:  BMC Cancer       Date:  2011-11-03       Impact factor: 4.430

8.  Balance between MKK6 and MKK3 mediates p38 MAPK associated resistance to cisplatin in NSCLC.

Authors:  Eva M Galan-Moya; Miguel A de la Cruz-Morcillo; Maria Llanos Valero; Juan L Callejas-Valera; Pedro Melgar-Rojas; Javier Hernadez Losa; Mayte Salcedo; Antonio Fernández-Aramburo; Santiago Ramon y Cajal; Ricardo Sánchez-Prieto
Journal:  PLoS One       Date:  2011-12-02       Impact factor: 3.240

9.  MKP1 mediates chemosensitizer effects of E1a in response to cisplatin in non-small cell lung carcinoma cells.

Authors:  Francisco J Cimas; Juan L Callejas-Valera; Raquel Pascual-Serra; Jesus García-Cano; Elena Garcia-Gil; Miguel A De la Cruz-Morcillo; Marta Ortega-Muelas; Leticia Serrano-Oviedo; J Silvio Gutkind; Ricardo Sánchez-Prieto
Journal:  Oncotarget       Date:  2015-12-29

10.  MKP1: Jekyll and Hyde for E1A.

Authors:  Francisco J Cimas; Juan Callejas-Valera Luis Callejas-Valera; Ricardo Sanchez-Prieto
Journal:  Aging (Albany NY)       Date:  2016-02       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.